Qureight, a biotech company from Cambridge, UK, secured $8.5M in Series A funding.

The round was led by Hargreave Hale AIM VCT, with notable participation from XTX Ventures, Guinness Ventures, and others.

The funds will support Qureight's efforts in expanding operations and advancing R&D, particularly in clinical trial development through AI-powered data analysis.

Qureight, led by CEO Dr. Muhunthan Thillai, partners with major pharma firms like AstraZeneca and has signed R&D contracts with five NHS England trusts.